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Background:  To describe the incidence rates of gastrointestinal (GI) cancers following the diagnoses of GI bleeding in patients receiving 
clopidogrel or warfarin.
Method: A retrospective study was conducted using the Thomson MedStat claims database from Sep 2004 to Jun 2009. Two user cohorts were 
created, consisting of patients with at least a 30-day supply of clopidogrel or warfarin. Two non-user cohorts not prescribed with any antiplatelets 
or anticoagulants were matched on age, gender, and insurance type with the clopidogrel and warfarin patients, respectively. Patients were followed 
from the first bleeding event after cohort entry until the earliest occurrence of the following: the end of the study period, disenrollment from the 
database, death, or the first event of GI cancer. The GI cancer incidence rates were calculated by <6 mo., 6-12 mo., and >12 mo. intervals following 
the diagnosis of GI bleeding and expressed as per 1,000 person yrs.
Results:  In the clopidogrel cohort, the newly diagnosed GI cancer incidence rate was the highest within 6 mo. (6.23/per 1,000 person-yrs) 
following the diagnosis of GI bleeding, and reduced approximately 16 fold afterwards (6-12 mo.: 0.36/1,000 person yrs, >12 mo.: 0.37/1,000 
person yrs). In the clopidogrel-matched non-user cohort, the GI cancer incidence rates during the 3 time intervals showed a similar pattern, but were 
15 times lower compared to the corresponding rates in the clopidogrel cohort (0.33, 0.02, and 0.05/ 1,000 person yrs, respectively). The GI cancer 
incidence rates in the warfarin and warfarin-matched non-user cohorts were similar to those in the clopidogrel and clopidogrel-matched non-user 
cohorts.
Conclusion: The incidence rates of GI cancers in the clopidogrel, warfarin, and the two matched non-user cohorts were the highest within the first 
6 mo. following the diagnoses of GI bleeding and tapered off in the periods afterwards. This pattern of the GI cancer incidence rates suggests that 
the diagnosis of previous GI bleeding is likely to increase the rate of detection of GI cancers and that the higher propensity for bleeding resulting 
from anti-platelets or anti-coagulants contributes to higher rate of detection of GI cancers.
